Pembrolizumab + Poly-ICLC in MRP Colon Cancer

NCT02834052 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colon Cancer
Solid Tumor

Interventions

DRUG: pembrolizumab
DRUG: Poly-ICLC

Sponsor

Asha Nayak

Collaborators

[object Object]
[object Object]